Cassandra Romano
Women's Health · Allentown, PANPI 1710524558
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $702 of the $802 with a category attached, or 87.5%. 14 manufacturers reported payments, led by AbbVie at 27.9% of the total. Reporting peaked in 2022 at $339 and has fallen 93.2% since, to $23 in 2024.
Across 36 payments — averaging $22.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$224
- Mayne Pharma Commercial LLC$135
- Astellas Pharma US Inc$120
- Sumitomo Pharma America, Inc.$84
- Myovant Sciences Inc.$41
- Aspira Women's Health Inc$33
- plus $167 from 8 others
What the payments were for
- Food & beverage$70288%
- Education$10012%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 11 | $224 |
| Mayne Pharma Commercial LLC | 8 | $135 |
| Astellas Pharma US Inc | 2 | $120 |
| Sumitomo Pharma America, Inc. | 3 | $84 |
| Myovant Sciences Inc. | 2 | $41 |
| Aspira Women's Health Inc | 1 | $33 |
| Smith+Nephew | 2 | $31 |
| Boston Scientific | 1 | $23 |
| Exeltis, USA Inc. | 1 | $23 |
| Therapeuticsmd, Inc. | 1 | $21 |
| Mylan Pharmaceuticals Inc. | 1 | $19 |
| Amgen | 1 | $18 |
| Evofem Biosciences, Inc. | 1 | $17 |
| Axonics, Inc. | 1 | $15 |
How this compares
$802 in reported general payments places this provider in the 75th percentile of 250 women's health providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Estradiol | 123 | $8,339 |
| Clobetasol Propionate | 47 | $1,896 |
| Metronidazole | 46 | $1,337 |
| Fluconazole | 67 | $1,014 |
| ValacyclovirValacyclovir Hcl | 27 | $912 |
| Gabapentin | 12 | $80 |
| Triamcinolone Acetonide | 16 | $70 |
Paid to pharmacies, not to this prescriber.
Other women's health in Allentown
- Caroline GarrisonAllentown$4K
- Shawana MoorePhiladelphia$72K
- Anita BoothFarrell$12K
- Kassandra PetitPhiladelphia$10K
- Mary WangPhiladelphia$8K
- Megan LaniganMechanicsburg$6K
- Lauren OppenheimBryn Mawr$5K
- Prisca SchneiderBryn Mawr$4K
- Karin YoungPittsburgh$4K
- Renata EstesHorsham$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.